… Patricia B Lehane7 … Patients who remained B cell depleted after this time were followed
until peripheral B cells returned to lower limit of normal or baseline, whichever occurred earlier. …

Objective. Final evaluation of the longterm safety of rituximab (RTX) in rheumatoid arthritis (RA)
up to 11 years. Methods. Pooled observed case analysis of data from patients with …

This report assesses the observed risk of PML in patients treated with the anti-CD20
monoclonal antibody rituximab in the regulatory authority-approved autoimmune indications …

Objective. This 5-year observational posthoc analysis of the REFLEX study and its open-label
extension assessed clinical efficacy, radiographic response, and safety of rituximab (RTX) …

Objective To assess the safety, tolerability, pharmacokinetics, and efficacy of rituximab (RTX)
in pediatric patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis …

Objective The present study was undertaken to conduct a phase IV, open‐label, prospective
study to characterize the long‐term safety of rituximab in a 4‐year observational registry of …

Introduction Patients with rheumatoid arthritis (RA) are at an increased risk of developing
malignancies, but it is unclear whether this increased risk is the result of disease pathobiology …

Introduction The aim of this work was to assess the impact of prolonged low immunoglobulin
(IgG or IgM) serum concentrations on the potential cumulative serious infection (SI) risk in …

Anti‐neutrophil cytoplasmic antibody‐associated vasculitides granulomatosis with
polyangiitis (GPA) and microscopic polyangiitis (MPA) are rare, potentially organ‐ and life‐…

… Berger, Vineeta Malik, Stuart Lacey, Paul Brunetta, and Patricia B. Lehane 3 , was
originally published electronically on the publisher’s internet portal (currently SpringerLink). …